Ciplox 250 mg Research Overview
Ciplox 250 mg is a pharmaceutical-grade ciprofloxacin formulation manufactured by Cipla for laboratory research applications. This fluoroquinolone antibiotic compound represents a critical tool for researchers investigating bacterial resistance mechanisms, antimicrobial efficacy profiles, and fluoroquinolone pharmacology in controlled laboratory environments. Each tablet contains precisely 250 mg of ciprofloxacin hydrochloride, enabling consistent research protocols across multiple studies. Laboratory researchers frequently examine ciprofloxacin’s broad-spectrum antibacterial properties against both gram-positive and gram-negative bacterial strains in culture studies. When sourcing research chemicals from Stroid UK Shop, investigators can access pharmaceutical-grade compounds that meet rigorous quality standards for academic and commercial research applications.
Laboratory Research Applications
Research scientists evaluate Ciplox 250 mg in various experimental contexts, particularly antimicrobial susceptibility testing and bacterial culture studies. This ciprofloxacin preparation enables investigations into DNA gyrase inhibition mechanisms, bacterial topoisomerase II interactions, and fluoroquinolone resistance development patterns in laboratory settings. Microbiologists study ciprofloxacin’s efficacy against diverse bacterial species including Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus aureus strains in controlled culture environments. Additionally, researchers examine this compound’s stability profiles under different storage conditions and pH environments. Many laboratories incorporate ciprofloxacin studies when investigating combination antimicrobial therapies or examining synergistic effects with other antibacterial agents. Scientists exploring antibacterial drugs often require standardised ciprofloxacin preparations for comparative efficacy assessments.
Product Specifications
| Parameter | Specification |
|---|---|
| Active Ingredient | Ciprofloxacin Hydrochloride |
| Strength | 250 mg per tablet |
| Manufacturer | Cipla Limited |
| Formulation | Film-coated tablet |
| CAS Number | 86393-32-0 |
| Molecular Formula | C₁₇H₁₈FN₃O₃·HCl |
| Storage | Room temperature, dry conditions |
Laboratory protocols require precise compound identification and purity verification before experimental use. Researchers frequently cross-reference pharmaceutical preparations with established reference standards to ensure experimental validity. Unlike research into SARMs or peptides, antibacterial studies demand pharmaceutical-grade preparations that maintain consistent potency throughout extended storage periods.
Laboratory Compliance Statement
Ciplox 250 mg is supplied exclusively for in-vitro laboratory research and analytical testing purposes. This product is not intended for human consumption, therapeutic use, or any application outside controlled laboratory environments. Researchers must ensure appropriate biosafety protocols and waste disposal procedures when handling antimicrobial compounds. All experimental work must comply with institutional biosafety guidelines and relevant antimicrobial research regulations.
